Developer docs
API playgroundTry for free, no card

Search company profiles

TheraVet

Full company profile

uuid000tlun

Namestring
TheraVet
Legal namestring
TheraVet S.A.
Websiteurl
thera.vet
Company typeenum
Private
Founded yearint
2017
Descriptiontext

TheraVet S.A. is a Belgian veterinary biotechnology company headquartered in Gosselies (Wallonia, Belgium) that develops and commercializes biomaterial-based treatments for osteoarticular diseases in companion animals (dogs, cats, and horses). The company's core technology is a proprietary line of injectable, self-hardening phosphocalcic (alpha-tricalcium phosphate, alpha-TCP) bone void fillers marketed under the BIOCERA-VET brand, positioned as alternatives to autologous bone grafts that avoid the morbidity of a second surgical site. The commercial product family comprises BIOCERA-VET BONE SURGERY RTU for general orthopedic procedures (arthrodesis, fractures, corrective osteotomy, TTA), BIOCERA-VET GRANULES and BIOCERA-VET SMARTGRAFT for bone grafting, BIOCERA-VET OSTEOSARCOMA RTU for canine osteosarcoma, and BIOCERA-VET COMBO/COMBO-CLEAN, a local sustained-release antibiotic-releasing bone substitute launched in 2023. A pipeline product, VISCO-VET (intra-articular injectable gel based on hyaluronic acid, species-specific plasma and an active pharmaceutical component), targets osteoarthritis and remains under investigation without market authorization.

TheraVet makes money through B2B sales of BIOCERA-VET devices and consumables to veterinary practices and specialty hospitals, distributed via a mix of direct e-commerce (bioceravet.com) and an extensive partner network that includes an international agreement with Vetpharma covering 24 countries, alongside regional partners in Italy (Alcyon Italia), Spain (Nuzoa), France (Elvetis), the UK and Ireland (Veterinary Instrumentation) and an exclusive US distributor. The company has a wholly-owned US subsidiary to support North American operations. Customers are companion-animal veterinarians and referral hospitals performing orthopedic and oncologic surgery; pain points addressed include the limitations of conventional bone grafts (availability, donor-site pain, infection risk) and the lack of limb-sparing options for canine osteosarcoma patients. Market context is sizable — osteoarthritis reportedly affects more than 34 million dogs worldwide and cranial cruciate ligament deficiency affects over 4 million — but TheraVet itself is a sub-50-employee private firm that does not publicly disclose revenue, and the credibility of the financial figures supplied in the source material is highly questionable (orders of magnitude inconsistent with the firm's size).

Short descriptiontext

TheraVet is a Belgian veterinary biotech that develops and commercializes injectable phosphocalcic (alpha-TCP) bone substitutes and related regenerative products for companion animals, sold through direct e-commerce and a 24-country distributor network to veterinary practices and specialty hospitals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGosselies, Belgium
HQ citystring
Gosselies
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary bone substitutes, animal orthopedic treatments, veterinary biomaterials, companion animal therapeutics, veterinary medical devices
Industry3 codes
PRIMARYHLAMAFAE
Orthopedic & Implantable Devices (Plates, Screws, TPLO, Prosthetics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Medical Devices & Supplies
SECONDARYHLAMANAC
Tissue Engineering & Biomaterial Scaffolds
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAMANAL
Clinical Research, Trials & Translational Services (Veterinary Regenerative)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Veterinary Orthopedic Products
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1BIOCERA-VET Product Sales
TypeOne Time License
Description

Sale of bone substitute products including BIOCERA-VET Bone Surgery RTU, BIOCERA-VET Granules, BIOCERA-VET Smartgraft, BIOCERA-VET Osteosarcoma RTU, and BIOCERA-VET COMBO (antibiotic releasing bone substitute). Products are sold through direct e-commerce and distribution partners.

thera.vet
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1BIOCERA-VET BONE SURGERY RTU
Description

Injectable self-hardening phosphocalcic bone void filler for bone surgery applications

thera.vet
+5 more records
Core offering1 text field

TheraVet develops and commercializes BIOCERA-VET, a proprietary line of injectable, self-hardening phosphocalcic (alpha-tricalcium phosphate) bone void fillers for veterinary orthopedic applications. The products are designed for bone surgery, fracture repair, osteosarcoma palliative treatment, and bone grafting in companion animals (dogs, cats, horses), and are sold through direct e-commerce and veterinary distributors across Europe and the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 300% increase in participating centers in Osteosarcoma Program within 6 months
+1 more record
Product overview1 text field

TheraVet is a vet biotech company offering a portfolio of bone substitute products under the BIOCERA-VET brand for companion animals (dogs, cats, and horses). The product line includes BIOCERA-VET BONE SURGERY RTU (ready-to-use injectable bone substitute for general orthopedic surgery), BIOCERA-VET GRANULES (granular bone graft formulation), BIOCERA-VET SMARTGRAFT (biological bone grafts), and BIOCERA-VET OSTEOSARCOMA RTU (specialized formulation for osteosarcoma treatment). Additional products include BIOCERA-VET COMBO and BIOCERA-VET COMBO-CLEAN (antibiotic-releasing bone substitutes). The company also has VISCO-VET, an intra-articular injectable gel based on hyaluronic acid and plasma, in its pipeline for osteoarthritis treatment.

Product and service6 records
1BIOCERA-VET
CategoryVeterinary bone substitute product line
Description

The full range of injectable self-hardening phosphocalcic bone void fillers with enhanced osteointegration, osteoinduction and bone remodeling properties for veterinary orthopedic applications in companion animals.

2BIOCERA-VET BONE SURGERY RTU
CategoryVeterinary bone substitute
Description

Ready-to-use injectable bone substitute for bone surgery applications including arthrodesis, fractures, corrective osteotomy, and TTA procedures in dogs and cats.

3BIOCERA-VET GRANULES
CategoryVeterinary bone substitute
Description

Granular bone graft substitute formulation within the BIOCERA-VET product line for veterinary orthopedic applications.

4BIOCERA-VET SMARTGRAFT
CategoryVeterinary bone substitute
Description

Innovative line of biological bone grafts within the BIOCERA-VET portfolio for veterinary applications.

5BIOCERA-VET OSTEOSARCOMA RTU
CategoryVeterinary bone substitute
Description

Ready-to-use bone substitute for palliative treatment of osteosarcoma in dogs, providing pain limitation and structural bone reinforcement.

6BIOCERA-VET COMBO / COMBO-CLEAN
CategoryVeterinary bone substitute
Description

Local and sustained antibiotic releasing bone substitute combining bone void filling with antibiotic delivery capabilities for veterinary orthopedic applications.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierRegional PartnerTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-09
Description

Distribution agreement for the BIOCERA-VET product line in Italy. Alcyon Italia distributes veterinary products and services in the Italian market.

Strategic tierClinical Research PartnerTypeStrategic or Co-development PartnerAnnounced on2023-11-23
Description

Launch of BIOCERA-VET Canine Osteosarcoma Study conducted by the University of Florida College of Veterinary Medicine.

Strategic tierProduct DevelopmentTypeOthersAnnounced on2023-05-31
Description

Commercial launch of BIOCERA-VET COMBO, a local and sustained antibiotic releasing bone substitute for veterinary orthopedic applications.

4Vetpharma
Strategic tierKey International PartnerTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-02-21
Description

International distribution agreement covering 24 countries for BIOCERA-VET products. Vetpharma is a veterinary pharmaceutical distribution network.

thera.vet
Strategic tierKey Strategic PartnerTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-09-26
Description

Exclusive distribution agreement for BIOCERA-VET in the United States. Commercial launch announced June 30, 2022.

6Veterinary Instrumentation
Strategic tierKey Distribution PartnerTypeChannel Partner/ Reseller/ Distributor
Description

Distribution agreement for BIOCERA-VET in UK and Ireland. Veterinary Instrumentation is a specialist in orthopaedics and surgical instrumentation.

thera.vet
Strategic tierRegional PartnerTypeChannel Partner/ Reseller/ Distributor
Description

Distribution agreement for BIOCERA-VET in Spain. Nuzoa is a leading Spanish company in distribution of veterinary products and services.

8Elvetis
Strategic tierRegional PartnerTypeChannel Partner/ Reseller/ Distributor
Description

Distribution agreement for BIOCERA-VET range in France. Elvetis is a veterinary distribution company.

thera.vet
Strategic tierResearch PartnerTypeStrategic or Co-development Partner
Description

Research and distribution collaboration for BIOCERA-VET product line expansion. INNOTERE is a German company specializing in biomaterials.

10Ter Braake
Strategic tierClinical PartnerTypeStrategic or Co-development Partner
Description

Partnership for assessment of BIOCERA-VET in horse bone cyst treatment. Located in the Netherlands.

thera.vet
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

German biomaterials company specializing in calcium-phosphate-based bone cements and substitutes (and an existing TheraVet research/distribution partner) — directly comparable on biomaterial technology and an ecosystem participant.

TypeDirect peer
Description

Veterinary biopharmaceutical company focused on developing biologic therapies for companion animals — comparable as a small-cap veterinary-biotech targeting chronic and osteoarticular conditions in dogs and cats.

TypeBroad incumbent
Description

Specialty veterinary pharmaceuticals company with a significant companion-animal endocrinology, dermatology and orthopedics portfolio — comparable as a European-headquartered specialty animal-health company overlapping with TheraVet's European distribution footprint.

TypeBroad incumbent
Description

Largest global animal-health company with a broad portfolio across companion-animal pharmaceuticals, biologics and devices — comparable as a broad incumbent that competes with TheraVet in veterinary orthopedic and pain-management categories.

TypeBroad incumbent
Description

Global animal-health company with a strong companion-animal portfolio including osteoarthritis and pain products (expanded via Aratana and KindredBio acquisitions) — comparable broad incumbent competing with TheraVet in canine orthopedics and OA.

TypeBroad incumbent
Description

French-headquartered global veterinary pharmaceutical company with companion-animal therapeutic products including orthopedic and pain indications — comparable as a mid-sized European animal-health peer operating in overlapping categories.

TypeDirect peer
Description

Veterinary medical device/biomaterials company marketing injectable implant products for osteoarthritis and orthopedic conditions in companion animals — closely comparable business model to TheraVet's injectable orthopedic biomaterials franchise.

TypeBroad incumbent
Description

Global veterinary pharmaceutical company headquartered in France with a broad companion-animal portfolio — comparable as a similarly sized European-rooted animal-health competitor active in canine orthopedics.

9Aratana Therapeutics
TypeDirect peer
Description

Veterinary biotech (now operating under Elanco) that developed biologic therapeutics for companion animals, including osteoarthritis and pain indications — directly comparable to TheraVet's positioning as a veterinary-biotech developing biologic therapies for canine musculoskeletal diseases.

10VetStem Biologics
TypeDirect peer
Description

Veterinary regenerative medicine company offering stem-cell based therapies for osteoarthritis, tendon/ligament injuries and orthopedic indications in dogs, cats and horses — directly comparable to TheraVet's BIOCERA-VET bone-substitute and pipeline osteoarthritis play.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TheraVet

Veterinary Orthopedic Productsthera.vet

TheraVet is a Belgian veterinary biotech that develops and commercializes injectable phosphocalcic (alpha-TCP) bone substitutes and related regenerative products for companion animals, sold through direct e-commerce and a 24-country distributor network to veterinary practices and specialty hospitals.

What TheraVet does

TheraVet S.A. is a Belgian veterinary biotechnology company headquartered in Gosselies (Wallonia, Belgium) that develops and commercializes biomaterial-based treatments for osteoarticular diseases in companion animals (dogs, cats, and horses). The company's core technology is a proprietary line of injectable, self-hardening phosphocalcic (alpha-tricalcium phosphate, alpha-TCP) bone void fillers marketed under the BIOCERA-VET brand, positioned as alternatives to autologous bone grafts that avoid the morbidity of a second surgical site. The commercial product family comprises BIOCERA-VET BONE SURGERY RTU for general orthopedic procedures (arthrodesis, fractures, corrective osteotomy, TTA), BIOCERA-VET GRANULES and BIOCERA-VET SMARTGRAFT for bone grafting, BIOCERA-VET OSTEOSARCOMA RTU for canine osteosarcoma, and BIOCERA-VET COMBO/COMBO-CLEAN, a local sustained-release antibiotic-releasing bone substitute launched in 2023. A pipeline product, VISCO-VET (intra-articular injectable gel based on hyaluronic acid, species-specific plasma and an active pharmaceutical component), targets osteoarthritis and remains under investigation without market authorization.

TheraVet makes money through B2B sales of BIOCERA-VET devices and consumables to veterinary practices and specialty hospitals, distributed via a mix of direct e-commerce (bioceravet.com) and an extensive partner network that includes an international agreement with Vetpharma covering 24 countries, alongside regional partners in Italy (Alcyon Italia), Spain (Nuzoa), France (Elvetis), the UK and Ireland (Veterinary Instrumentation) and an exclusive US distributor. The company has a wholly-owned US subsidiary to support North American operations. Customers are companion-animal veterinarians and referral hospitals performing orthopedic and oncologic surgery; pain points addressed include the limitations of conventional bone grafts (availability, donor-site pain, infection risk) and the lack of limb-sparing options for canine osteosarcoma patients. Market context is sizable — osteoarthritis reportedly affects more than 34 million dogs worldwide and cranial cruciate ligament deficiency affects over 4 million — but TheraVet itself is a sub-50-employee private firm that does not publicly disclose revenue, and the credibility of the financial figures supplied in the source material is highly questionable (orders of magnitude inconsistent with the firm's size).

TheraVet firmographics

Firmographics
Name
TheraVet
Legal name
TheraVet S.A.
Website
https://thera.vet
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
TheraVet is a Belgian veterinary biotech that develops and commercializes injectable phosphocalcic (alpha-TCP) bone substitutes and related regenerative products for companion animals, sold through direct e-commerce and a 24-country distributor network to veterinary practices and specialty hospitals.
Ownership category
akta.pro rank

TheraVet industry classification

Industry
Product category
Veterinary Orthopedic Products
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAMAFAE
Orthopedic & Implantable Devices (Plates, Screws, TPLO, Prosthetics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Medical Devices & Supplies
SECONDARYHLAMANAC
Tissue Engineering & Biomaterial Scaffolds
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAMANAL
Clinical Research, Trials & Translational Services (Veterinary Regenerative)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals

Keywords

  • Veterinary bone substitutes
  • Animal orthopedic treatments
  • Veterinary biomaterials
  • Companion animal therapeutics
  • Veterinary medical devices

Where TheraVet is headquartered

Location

Headquarters

HQ city
Gosselies
HQ country
Belgium
HQ region
Europe

Offices2 records

Markets served

TheraVet business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. BIOCERA-VET Product Sales: Sale of bone substitute products including BIOCERA-VET Bone Surgery RTU, BIOCERA-VET Granules, BIOCERA-VET Smartgraft, BIOCERA-VET Osteosarcoma RTU, and BIOCERA-VET COMBO (antibiotic releasing bone substitute). Products are sold through direct e-commerce and distribution partners.

Go-to-market motion1 record

Distribution channels7 records

Marketing channels7 records

TheraVet product offering

Product offering

Core offering

TheraVet develops and commercializes BIOCERA-VET, a proprietary line of injectable, self-hardening phosphocalcic (alpha-tricalcium phosphate) bone void fillers for veterinary orthopedic applications. The products are designed for bone surgery, fracture repair, osteosarcoma palliative treatment, and bone grafting in companion animals (dogs, cats, horses), and are sold through direct e-commerce and veterinary distributors across Europe and the United States.

Product overview

TheraVet is a vet biotech company offering a portfolio of bone substitute products under the BIOCERA-VET brand for companion animals (dogs, cats, and horses). The product line includes BIOCERA-VET BONE SURGERY RTU (ready-to-use injectable bone substitute for general orthopedic surgery), BIOCERA-VET GRANULES (granular bone graft formulation), BIOCERA-VET SMARTGRAFT (biological bone grafts), and BIOCERA-VET OSTEOSARCOMA RTU (specialized formulation for osteosarcoma treatment). Additional products include BIOCERA-VET COMBO and BIOCERA-VET COMBO-CLEAN (antibiotic-releasing bone substitutes). The company also has VISCO-VET, an intra-articular injectable gel based on hyaluronic acid and plasma, in its pipeline for osteoarthritis treatment.

Differentiator

Problem solved

Functional benefit

Brands

  • BIOCERA-VET BONE SURGERY RTU: Injectable self-hardening phosphocalcic bone void filler for bone surgery applications
  • BIOCERA-VET GRANULES
  • BIOCERA-VET SMARTGRAFT
  • BIOCERA-VET OSTEOSARCOMA RTU
  • BIOCERA-VET COMBO-CLEAN
  • VISCO-VET

Products and services

  • BIOCERA-VET The full range of injectable self-hardening phosphocalcic bone void fillers with enhanced osteointegration, osteoinduction and bone remodeling properties for veterinary orthopedic applications in companion animals.
  • BIOCERA-VET BONE SURGERY RTU Ready-to-use injectable bone substitute for bone surgery applications including arthrodesis, fractures, corrective osteotomy, and TTA procedures in dogs and cats.
  • BIOCERA-VET GRANULES Granular bone graft substitute formulation within the BIOCERA-VET product line for veterinary orthopedic applications.
  • BIOCERA-VET SMARTGRAFT Innovative line of biological bone grafts within the BIOCERA-VET portfolio for veterinary applications.
  • BIOCERA-VET OSTEOSARCOMA RTU Ready-to-use bone substitute for palliative treatment of osteosarcoma in dogs, providing pain limitation and structural bone reinforcement.
  • BIOCERA-VET COMBO / COMBO-CLEAN Local and sustained antibiotic releasing bone substitute combining bone void filling with antibiotic delivery capabilities for veterinary orthopedic applications.

Quantifiable outcome

  • 300% increase in participating centers in Osteosarcoma Program within 6 months
  • +1 more outcomes

Companies that use TheraVet

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

TheraVet technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

TheraVet partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered regional partner, clinical research partner, product development, key international partner, key strategic partner, key distribution partner, research partner and clinical partner.

  • Alcyon Italiaregional partnerChannel Partner/ Reseller/ Distributor · 9 January 2024Distribution agreement for the BIOCERA-VET product line in Italy. Alcyon Italia distributes veterinary products and services in the Italian market.
  • University of Floridaclinical research partnerStrategic or Co-development Partner · 23 November 2023Launch of BIOCERA-VET Canine Osteosarcoma Study conducted by the University of Florida College of Veterinary Medicine.
  • BIOCERA-VET COMBO Product Launchproduct developmentOthers · 31 May 2023Commercial launch of BIOCERA-VET COMBO, a local and sustained antibiotic releasing bone substitute for veterinary orthopedic applications.
  • Vetpharmakey international partnerChannel Partner/ Reseller/ Distributor · 21 February 2023International distribution agreement covering 24 countries for BIOCERA-VET products. Vetpharma is a veterinary pharmaceutical distribution network.
  • US Distribution Partnerkey strategic partnerChannel Partner/ Reseller/ Distributor · 26 September 2022Exclusive distribution agreement for BIOCERA-VET in the United States. Commercial launch announced June 30, 2022.
  • Veterinary Instrumentationkey distribution partnerChannel Partner/ Reseller/ DistributorDistribution agreement for BIOCERA-VET in UK and Ireland. Veterinary Instrumentation is a specialist in orthopaedics and surgical instrumentation.
  • Nuzoaregional partnerChannel Partner/ Reseller/ DistributorDistribution agreement for BIOCERA-VET in Spain. Nuzoa is a leading Spanish company in distribution of veterinary products and services.
  • Elvetisregional partnerChannel Partner/ Reseller/ DistributorDistribution agreement for BIOCERA-VET range in France. Elvetis is a veterinary distribution company.
  • INNOTEREresearch partnerStrategic or Co-development PartnerResearch and distribution collaboration for BIOCERA-VET product line expansion. INNOTERE is a German company specializing in biomaterials.
  • Ter Braakeclinical partnerStrategic or Co-development PartnerPartnership for assessment of BIOCERA-VET in horse bone cyst treatment. Located in the Netherlands.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

TheraVet competitors and assessment

Company assessment

Others

  • INNOTERE: German biomaterials company specializing in calcium-phosphate-based bone cements and substitutes (and an existing TheraVet research/distribution partner) — directly comparable on biomaterial technology and an ecosystem participant.

Direct peers

  • Kindred Biosciences: Veterinary biopharmaceutical company focused on developing biologic therapies for companion animals — comparable as a small-cap veterinary-biotech targeting chronic and osteoarticular conditions in dogs and cats.
  • PetVivo Holdings: Veterinary medical device/biomaterials company marketing injectable implant products for osteoarthritis and orthopedic conditions in companion animals — closely comparable business model to TheraVet's injectable orthopedic biomaterials franchise.
  • Aratana Therapeutics: Veterinary biotech (now operating under Elanco) that developed biologic therapeutics for companion animals, including osteoarthritis and pain indications — directly comparable to TheraVet's positioning as a veterinary-biotech developing biologic therapies for canine musculoskeletal diseases.
  • VetStem Biologics: Veterinary regenerative medicine company offering stem-cell based therapies for osteoarthritis, tendon/ligament injuries and orthopedic indications in dogs, cats and horses — directly comparable to TheraVet's BIOCERA-VET bone-substitute and pipeline osteoarthritis play.

Broad incumbents

  • Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company with a significant companion-animal endocrinology, dermatology and orthopedics portfolio — comparable as a European-headquartered specialty animal-health company overlapping with TheraVet's European distribution footprint.
  • Zoetis: Largest global animal-health company with a broad portfolio across companion-animal pharmaceuticals, biologics and devices — comparable as a broad incumbent that competes with TheraVet in veterinary orthopedic and pain-management categories.
  • Elanco Animal Health: Global animal-health company with a strong companion-animal portfolio including osteoarthritis and pain products (expanded via Aratana and KindredBio acquisitions) — comparable broad incumbent competing with TheraVet in canine orthopedics and OA.
  • Vetoquinol: French-headquartered global veterinary pharmaceutical company with companion-animal therapeutic products including orthopedic and pain indications — comparable as a mid-sized European animal-health peer operating in overlapping categories.
  • Virbac: Global veterinary pharmaceutical company headquartered in France with a broad companion-animal portfolio — comparable as a similarly sized European-rooted animal-health competitor active in canine orthopedics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

TheraVet social profiles

Digital presence

TheraVet compliance and trust

Trust signal

Compliance1 record

TheraVet financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TheraVet leadership team

Management profile

Number of profiles

Profiles9 records

TheraVet subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

TheraVet funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TheraVet M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TheraVet

What does TheraVet do?

TheraVet develops and commercializes BIOCERA-VET, a proprietary line of injectable, self-hardening phosphocalcic (alpha-tricalcium phosphate) bone void fillers for veterinary orthopedic applications. The products are designed for bone surgery, fracture repair, osteosarcoma palliative treatment, and bone grafting in companion animals (dogs, cats, horses), and are sold through direct e-commerce and veterinary distributors across Europe and the United States.

Is TheraVet a public or private company?

TheraVet is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was TheraVet founded?

TheraVet was founded in 2017. It employs 1 to 10 people.

Where is TheraVet based?

TheraVet is headquartered in Gosselies, Belgium, in the Europe region.

How does TheraVet make money?

One revenue line is on record: BIOCERA-VET Product Sales.

Who are TheraVet's main competitors?

INNOTERE is listed as an others. Direct peers are Kindred Biosciences, PetVivo Holdings, Aratana Therapeutics and VetStem Biologics. Broad incumbents are Dechra Pharmaceuticals, Zoetis, Elanco Animal Health, Vetoquinol and Virbac.

Does TheraVet have an API?

No public API is recorded for TheraVet.

What industry is TheraVet in?

TheraVet's product category is Veterinary Orthopedic Products. Its primary akta.pro industry code is HLAMAFAE, Orthopedic & Implantable Devices (Plates, Screws, TPLO, Prosthetics), with a secondary code of HLAMANAC, Tissue Engineering & Biomaterial Scaffolds. Its NAICS code is 325414 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals